News about "AbbVie"

AbbVie Wins EU Approval for TEPKINLY in Combination with Lenalidomide and Rituximab

The European Commission has approved AbbVie's TEPKINLY with lenalidomide and rituximab as the first bispecific, chemotherapy-free treatment for Relapsed or Refractory Follicular Lymphoma in the second-line setting.

AbbVie | 07/07/2026 | By News Bureau

AbbVie Reports Positive Phase 3 Results for Epcoritamab in Diffuse Large B-Cell Lymphoma

AbbVie reported positive phase 3 results for epcoritamab plus lenalidomide, showing improved Progression-Free Survival (PFS) in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).

AbbVie | 01/07/2026 | By News Bureau

European Commission Approves AbbVie's MAVIRET for Acute Hepatitis C

The European Commission (EC) has approved AbbVie’s MAVIRET for acute Hepatitis C Virus (HCV) infection, enabling earlier treatment initiation to help reduce disease progression, cirrhosis, and liver cancer risk.

AbbVie | 24/06/2026 | By News Bureau

AbbVie to Acquire Apogee Therapeutics

AbbVie plans to acquire Apogee Therapeutics, expanding its immunology portfolio with a diverse pipeline of innovative therapies for dermatologic, respiratory, inflammatory, and immune-mediated diseases.

AbbVie | 23/06/2026 | By News Bureau

Allergan Aesthetics Secures US FDA Approval for Skinvive to Treat Neck Wrinkles

Allergan Aesthetics has received the US Food and Drug Administration (FDA) approval for Skinvive by Juvéderm to reduce neck wrinkles and improve overall neck appearance. The injectable treatment helps the skin retain moisture, softness and smoothness, providing a first-of-its-kind option for addressing age-related and ‘tech-neck’ lines.

AbbVie | 18/06/2026 | By News Bureau

EU Approves AQUIPTA for Acute Migraine Treatment in Adults

The EC has approved AQUIPTA (atogepant) for the acute treatment and prevention of migraine in adults, based on phase 3 ECLIPSE trial results demonstrating rapid pain relief, sustained efficacy, and consistent benefits across multiple migraine attacks. The approval expands AbbVie’s migraine treatment portfolio across EU.

AbbVie | 03/06/2026 | By News Bureau

US FDA Approves DECNUPAZ for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

AbbVie has received US FDA approval for DECNUPAZ to treat adults with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), marking the first and only outpatient-initiated ADC for BPDCN and AbbVie’s first approved Antibody Drug Conjugate (ADC) for hematologic malignancies.

AbbVie | 30/05/2026 | By News Bureau

AbbVie Receives Positive CHMP Opinion for MAVIRET in Acute Hepatitis C Treatment

AbbVie receives a positive CHMP opinion for MAVIRET to treat acute hepatitis C, supported by Phase 3 data demonstrating safety and efficacy in adults with acute HCV infection.

AbbVie | 26/05/2026 | By News Bureau |  122

AbbVie Provides US Regulatory Update on TrenibotE BLA

AbbVie gets US FDA Complete Response Letter (CRL) for TrenibotE BLA tied to manufacturing processes; no new clinical studies needed.

AbbVie | 24/04/2026 | By News Bureau |  107

Haisco Signs Exclusive Deal with AbbVie to Develop Novel Pain Therapies

Haisco partners with AbbVie to develop novel pain therapies, with multiple compounds in preclinical to Phase 1 stages targeting pain-related conditions.

AbbVie | 13/04/2026 | By News Bureau |  148